Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyAntilymphocyte immunoglobulin (horse)
Identification
- Name
- Antilymphocyte immunoglobulin (horse)
- Accession Number
- DB09312
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Description
Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The result is polyclonal IgG that is then purified from the horse's serum to produce a usable drug product that can be used for immunosuppression. Although the exact mechanism of action is unknown, equine anti-thymocyte globulin targets a variety of immune system proteins including lymphocyte surface proteins, granulocytes, platelets, bone marrow cells, and other cell types. Equine ATG is currently indicated for the suppression of the immune system to prevent renal transplant rejection and in the treatment of aplastic anemia. Induction of T cell apoptosis and resulting T-cell lymphopenia found in vivo is credited for its therapeutic effect in these conditions.
There are currently various ATG products available, which differ in the source of inoculated animal (rabbit, horse, or pig) and in the type of antigen product used to produce immunoglobulin (thymocytes, peripheral T cells, etc.).
- Protein chemical formula
- Not Available
- Protein average weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Anti-thymocyte Globulin (Equine)
- Anti-thymocyte globulin equine
- eATG
- equine ATG
- Equine thymocyte immune globulin
- hATG
- Horse anti-thymocyte globulin
- Horse ATG
- Lymphocyte immune globulin anti-thymocyte globulin (equine)
- Lymphocyte immune globulin, anti-thymocyte globulin
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Atgam Solution 50 mg Intravenous Pfizer 1998-12-04 Not applicable Canada 
Atgam Injection, solution 50 mg/mL Intravenous Pharmacia & Upjohn Inc 1981-11-17 Not applicable US 
Atgam Sterile Solution IV 50mg/ml Liquid 50 mg Intravenous Pharmacia & Upjohn Inc 1985-12-31 1999-08-12 Canada - Categories
- Amino Acids, Peptides, and Proteins
- Antibodies
- Antineoplastic and Immunomodulating Agents
- Biological Products
- Blood
- Blood Proteins
- Body Fluids
- Complex Mixtures
- Fluids and Secretions
- Globulins
- Hemic and Immune Systems
- Immune Sera
- Immunoglobulin G
- Immunoglobulins
- Immunologic Factors
- Immunoproteins
- Immunosuppressive Agents
- Miscellaneous Therapeutic Agents
- Proteins
- Selective Immunosuppressants
- Serum
- Serum Globulins
- UNII
- 475247QF1Z
- CAS number
- Not Available
Pharmacology
- Indication
For prevention of renal transplant rejection and for the treatment of aplastic anemia.
- Associated Conditions
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
During infusion of 10 to 15 mg/kg/day, the mean peak value (n = 27 renal transplant patients) was found to be 727 ± 310 μg/mL.
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
The half-life of equine immunoglobulin after ATGAM infusion was found to be 5.7 ± 3.0 days in one group of recipients. The range for half-life was 1.5 to 13 days.
- Clearance
- Not Available
- Toxicity
The most commonly reported adverse reactions (occurring in greater than 10% of patients) are pyrexia, chills, rash, thrombocytopenia, leukopenia and arthralgia.
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group Anthrax immune globulin human The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Anthrax immune globulin human. Approved Bacillus calmette-guerin substrain connaught live antigen The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Bacillus calmette-guerin substrain tice live antigen The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Bacillus calmette-guerin substrain tice live antigen. Approved BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Antilymphocyte immunoglobulin (horse). Investigational Clostridium tetani toxoid antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated). Approved Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated). Approved Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Antilymphocyte immunoglobulin (horse). Approved Fingolimod Antilymphocyte immunoglobulin (horse) may increase the immunosuppressive activities of Fingolimod. Approved, Investigational G17DT The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with G17DT. Investigational GI-5005 The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with GI-5005. Investigational Hepatitis A Vaccine The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Hepatitis A Vaccine. Approved Hepatitis B Vaccine (Recombinant) The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Hepatitis B Vaccine (Recombinant). Approved, Withdrawn Human rabies virus immune globulin The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Human rabies virus immune globulin. Approved INGN 201 The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with INGN 201. Investigational INGN 225 The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with INGN 225. Investigational Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated). Approved Leflunomide The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Leflunomide. Approved, Investigational Natalizumab The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Natalizumab. Approved, Investigational Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Antilymphocyte immunoglobulin (horse). Approved, Investigational Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Antilymphocyte immunoglobulin (horse). Approved, Investigational Rabies virus inactivated antigen, A The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Rabies virus inactivated antigen, A. Approved, Investigational Rabies virus inactivated antigen, A The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Antilymphocyte immunoglobulin (horse). Approved, Investigational Rindopepimut The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Rindopepimut. Investigational Roflumilast Roflumilast may increase the immunosuppressive activities of Antilymphocyte immunoglobulin (horse). Approved Rotavirus Vaccine The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Rotavirus Vaccine. Approved Rubella virus vaccine The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Rubella virus vaccine. Approved, Investigational Salmonella typhi ty2 vi polysaccharide antigen The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Salmonella typhi ty2 vi polysaccharide antigen. Approved Salmonella typhi ty21a live antigen The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Salmonella typhi ty21a live antigen. Approved Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Antilymphocyte immunoglobulin (horse). Approved, Investigational SRP 299 The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with SRP 299. Investigational Tacrolimus Tacrolimus may increase the immunosuppressive activities of Antilymphocyte immunoglobulin (horse). Approved, Investigational Tecemotide The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Tecemotide. Investigational TG4010 The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with TG4010. Investigational Tofacitinib Antilymphocyte immunoglobulin (horse) may increase the immunosuppressive activities of Tofacitinib. Approved, Investigational Trastuzumab Trastuzumab may increase the neutropenic activities of Antilymphocyte immunoglobulin (horse). Approved, Investigational Typhoid Vaccine The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Typhoid Vaccine. Approved Varicella Zoster Vaccine (Live/Attenuated) The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Varicella Zoster Vaccine (Live/Attenuated). Approved Yellow Fever Vaccine The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Yellow Fever Vaccine. Approved, Investigational - Food Interactions
- Not Available
References
- General References
- Feng X, Scheinberg P, Biancotto A, Rios O, Donaldson S, Wu C, Zheng H, Sato K, Townsley DM, McCoy JP, Young NS: In vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia. Haematologica. 2014 Sep;99(9):1433-40. doi: 10.3324/haematol.2014.106542. Epub 2014 Jun 6. [PubMed:24907357]
- Vallejo C, Montesinos P, Polo M, Cuevas B, Morado M, Rosell A, Xicoy B, Diez JL, Salamero O, Cedillo A, Martinez P, Rayon C: Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis. Ann Hematol. 2015 Jun;94(6):947-54. doi: 10.1007/s00277-015-2305-3. Epub 2015 Feb 13. [PubMed:25672649]
- Hagen P, Wagner JE, DeFor TE, Dolan M, Arora M, Warlick E, Weisdorf D, Brunstein CG: The effect of equine antithymocyte globulin on the outcomes of reduced intensity conditioning for AML. Bone Marrow Transplant. 2014 Dec;49(12):1498-504. doi: 10.1038/bmt.2014.183. Epub 2014 Sep 22. [PubMed:25243623]
- Dubey S, Nityanand S: Involvement of Fas and TNF pathways in the induction of apoptosis of T cells by antithymocyte globulin. Ann Hematol. 2003 Aug;82(8):496-9. Epub 2003 May 29. [PubMed:12783210]
- External Links
- KEGG Drug
- D08808
- PubChem Substance
- 347910436
- RxList
- RxList Drug Page
- Wikipedia
- Anti-thymocyte_globulin
- ATC Codes
- L04AA03 — Antilymphocyte immunoglobulin (horse)
- AHFS Codes
- 92:00.00 — Miscellaneous Therapeutic Agents
- FDA label
- Download (4.88 MB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Injection, solution Intravenous 50 mg/mL Solution Intravenous 50 mg Liquid Intravenous 50 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Taxonomy
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
Drug created on November 16, 2015 15:18 / Updated on July 16, 2018 21:27